Inovio’s Co-Founder along with its Lead Antigen Designer Named Among Top 20 Researchers With Most Granted U.S Patents for ...
January 17 2018 - 8:00AM
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that Dr.
David B. Weiner, its co-founder; and Dr. Jian Yan, the company’s
Lead Antigen Designer, have been selected as two of the “Top 20
Translational Researchers” for the year 2016 by the editors of
Nature Biotechnology journal in its most recent published issue.
The annual selection is based on the number of medical innovations
that led to patents a researcher was granted in a calendar year.
The designation “translational researcher” refers to basic research
that can move from the lab bench to become patented medicine.
Dr. Weiner’s 16 patented innovations and Dr.
Yan’s nine granted U.S. patents in 2016 relate to advancing the
field of SynCon® immunotherapies and vaccines. Specifically, their
patents were related to innovative claims for cancer immunotherapy
indications targeting brain, bladder, head & neck, prostate and
other cancer types. In addition, their research led to
patented innovations for treating viral infections such as the
human papilloma virus (HPV), hepatitis B & C, HIV and
influenza. Several of these patents cover VGX-3100, which has
advanced to phase 3 pivotal trials, and INO-5401, which is in
immuno-oncology efficacy trials in combination with PD-1 and PD-L1
checkpoint inhibitors to treat glioblastoma and metastatic bladder
cancer.
Dr. J. Joseph Kim, Inovio's President and CEO,
said, "This is a truly well-deserved honor for Drs. Weiner and Yan.
This global recognition acknowledges Inovio’s innovation and
commitment to creating tomorrow’s medicines with a revolutionary
ASPIRE™ (Antigen SPecific Immune REsponses) platform. These
innovations and inventions have resulted in multiple clinical
trials, collaborations and partnerships. It also recognizes
Inovio’s intellectual property focus which has led to a strong
patent estate protecting our technology and commercial business
goals.”
Over his career, Dr. Weiner holds more than 100
issued and pending U.S. patents. As the Lead Antigen Designer at
Inovio, Dr. Yan has 24 granted patents and 17 pending patents. In
2016, Dr. Weiner joined The Wistar Institute, the nation’s first
independent biomedical research institute, an NCI-designated Cancer
Center, and an international leader in cancer, immunology and
infectious disease research, as Executive Vice President, Director
of its Vaccine Center and the W. W. Smith Charitable Trust Endowed
Professorship in Cancer Research. Dr. Weiner is Inovio’s
co-founder, board member and chair of its scientific advisory
board.
About Inovio Pharmaceuticals,
Inc.
Inovio is taking immunotherapy to the next level
in the fight against cancer and infectious diseases. We are the
only immunotherapy company that has reported generating T cells in
vivo in high quantity that are fully functional and whose killing
capacity correlates with relevant clinical outcomes with a
favorable safety profile. With an expanding portfolio of immune
therapies, the company is advancing a growing preclinical and
clinical stage product pipeline. Partners and collaborators include
MedImmune, Regeneron, Genentech, The Wistar Institute, University
of Pennsylvania, the Parker Institute for Cancer Immunotherapy,
DARPA, GeneOne Life Science, Plumbline Life Sciences, ApolloBio
Corporation, Drexel University, NIH, HIV Vaccines Trial Network,
National Cancer Institute, U.S. Military HIV Research Program, and
Laval University. For more information, visit www.inovio.com.
This press release contains certain
forward-looking statements relating to our business, including our
plans to develop electroporation-based drug and gene delivery
technologies and DNA vaccines, our expectations regarding our
research and development programs, including the planned initiation
and conduct of clinical trials and the availability and timing of
data from those trials, and the sufficiency of our capital
resources. Actual events or results may differ from the
expectations set forth herein as a result of a number of factors,
including uncertainties inherent in pre-clinical studies, clinical
trials and product development programs, the availability of
funding to support continuing research and studies in an effort to
prove safety and efficacy of electroporation technology as a
delivery mechanism or develop viable DNA vaccines, our ability to
support our pipeline of SynCon® active immunotherapy and vaccine
products, the ability of our collaborators to attain development
and commercial milestones for products we license and product sales
that will enable us to receive future payments and royalties, the
adequacy of our capital resources, the availability or potential
availability of alternative therapies or treatments for the
conditions targeted by the company or its collaborators, including
alternatives that may be more efficacious or cost effective than
any therapy or treatment that the company and its collaborators
hope to develop, issues involving product liability, issues
involving patents and whether they or licenses to them will provide
the company with meaningful protection from others using the
covered technologies, whether such proprietary rights are
enforceable or defensible or infringe or allegedly infringe on
rights of others or can withstand claims of invalidity and whether
the company can finance or devote other significant resources that
may be necessary to prosecute, protect or defend them, the level of
corporate expenditures, assessments of the company's technology by
potential corporate or other partners or collaborators, capital
market conditions, the impact of government healthcare proposals
and other factors set forth in our Annual Report on Form 10-K for
the year ended December 31, 2016, our Form 10-Q for the
period ended September 30, 2017, and other regulatory filings we
make from time to time. There can be no assurance that any product
candidate in Inovio's pipeline will be successfully developed,
manufactured or commercialized, that final results of clinical
trials will be supportive of regulatory approvals required to
market licensed products, or that any of the forward-looking
information provided herein will be proven accurate.
Forward-looking statements speak only as of the date of this
release, and Inovio undertakes no obligation to update or revise
these statements, except as may be required by law.
CONTACTS:
Investors: Ben Matone, Inovio, 484-362-0076,
ben.matone@inovio.comMedia: Jeff Richardson, Inovio, 267-440-4211,
jrichardson@inovio.com
Inovio Pharmaceuticals (NASDAQ:INO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Inovio Pharmaceuticals (NASDAQ:INO)
Historical Stock Chart
From Apr 2023 to Apr 2024